Optimum Strategic Communications
Optimum Strategic Communications
  • 29
  • 1 250
Targeting brain cancer using a high-precision radiopharmaceutical
Radiopharmaceuticals have hit the news recently thanks to their success in treating prostate cancer and neuroendocrine tumours.
Now Ariceum Therapeutics has joined forces with the NHS’s University College London Hospital (UCLH) to run a trial of a super high-precision radiopharmaceutical approach, called Auger therapy, in patients with recurrent glioblastoma, a type of brain cancer.
Watch Ariceum’s COO Greg Mullen explain Auger therapy and what they hope to show with the trial, in our latest edition of Optimum TV.
Переглядів: 14

Відео

Industry reviews: Optimum's 16th Annual Healthcare Investor Conference
Переглядів 1614 днів тому
Hear from industry leaders who attended Optimum's 16th Annual Healthcare Investor Conference 2024. The industry leading event highlighted the life sciences feel good factor for 2025.
A novel way to tackle Huntington’s disease
Переглядів 2228 днів тому
Huntington’s disease is a rare - but not that rare - inherited, neurological condition causing debilitating movement disorders, psychiatric problems and, ultimately, death. Cambridge-based LoQus23 Therapeutics, which is developing a disease-modifying treatment for the condition, has secured £35m in a Series A round led by Forbion, alongside existing investors SV Health Investors’ Dementia Disco...
The Optimum TV ‘Countdown-to-Conference’ mini-series - Part 5
Переглядів 9Місяць тому
Watch Allan Marchington, MD and Head of Life Sciences ICG, talk to Optimum TV about how the life science market is “climbing back out” after a difficult couple of years. “In terms of the market overall, people are being a little bit more choosy about where they invest” than in the past, he said. But as the year moves towards its conclusion “I think the pace is going to step up,” he predicted.
The Optimum TV ‘Countdown-to-Conference’ mini-series - Part 4
Переглядів 12Місяць тому
Watch Francesco De Rubertis, co-founder and Partner at Medicxi, talk to # OptimumTV about how the market for life science companies moves in waves, why M&A is more popular than IPOs right now, and his thoughts on the next big things in the treatment of cancer and autoimmune diseases.
The Optimum TV ‘Countdown to Conference’ mini-series - Part 3
Переглядів 152 місяці тому
Watch Dr Daniel Mahony talk to Optimum TV about Novo Holdings’ recent investment in publicly-listed DNA / RNA sequencing company Oxford Nanopore, and his thoughts on how life science markets are developing in 2024.
The Optimum TV ‘Countdown-to-Conference’ mini-series - Part 2
Переглядів 172 місяці тому
Market turbulence is to be expected and should not derail the “cautious optimism” the life science sector has seen so far in 2024. EQT’s Geraldine O’Keeffe tells the latest in part 2 of OptimumTV's ‘Countdown to Conference’ mini-series.
The Optimum TV ‘Countdown-to-Conference’ mini-series - Part 1
Переглядів 133 місяці тому
The first in our ‘Countdown-to-Conference’ mini-series, we join the brilliant Kieran Murphy, former CEO of GE Healthcare and now Chairman of a number of life science companies, including Gamma Biosciences, SPT Labtech and Centiva, and hear his views on the state of play of the life sciences market. Over the coming months, we will be interviewing a number of the leading experts who are panellist...
How a pill can boost the chance of having a baby following IVF / ICSI fertility treatment
Переглядів 143 місяці тому
Fertility treatment is very common nowadays - but all too often ends in failure. In our latest episode of Optimum TV, Dr Agnès Arbat of Oxolife describes positive Phase 2 results for a non-hormonal pill the Spanish biotech has developed, which increases the chance of success by helping the embryo implant in the uterus.
How does a British biotech raise £90m in a Series A? It’s as easy as ADC
Переглядів 283 місяці тому
In the latest episode of Optimum TV, Michael Bauer, Partner at Novo Holdings Venture Investments, explains why the investor was so keen on British biotech Myricx Bio, a spin-out from Imperial College and the Francis Crick Institute. Myricx has concluded a staggering £90m Series A round, led by Novo Holdings, to develop ADCs which use an entirely new class of payload based on its NMT-inhibitor t...
New treatment beckons for cutaneous T-cell lymphoma (CTCL)With Jason Loveridge, CEO of 4SC
Переглядів 1414 місяці тому
In the latest episode of #OptimumTV, 4SC’s CEO Jason Loveridge talks about the company’s plans to bring its drug resminostat to market for the treatment of CTCL, a type of non-Hodgkin’s lymphoma that affects the skin.
Creating exceptional antibody-based drugs by interrogating the immune responses to disease
Переглядів 184 місяці тому
Watch our latest episode of Optimum TV, in which Stefano Gulla, CSO of Amsterdam-based Kling Biotherapeutics, describes how Kling is creating exceptional antibody-based drugs by interrogating the immune responses of ‘elite responders’ to disease.
Commit Biologics - Harnessing the body’s complement system to tackle cancer and autoimmune disease
Переглядів 184 місяці тому
Commit Bio, spun out from Denmark’s Aarhus University in 2021, has developed a new way of harnessing a part of the body’s immune system - called the complement system - to fight cancer and autoimmune disease. Commit Bio’s CEO, Krishna Polu outlines to Stephen Adams on #OptimumTV how their BICE technology is used to “supercharge” conventional antibodies and the progress the company aims to make ...
STORM Therapeutics- Modifying RNA with small molecule drugs: a new approach to immunotherapy
Переглядів 594 місяці тому
Thanks to Covid vaccines, everyone’s now heard of RNA. But did you know that cellular reprogramming through RNA modifications can help to combat and treat diseases including cancers and - potentially - Alzheimer’s? Watch Jerry McMahon, CEO of Cambridge (UK) based STORM Therapeutics, speaking in our latest edition of Optimum TV about the company’s approach and why STORM is leading the field in t...
How to “build” a new blood vessel - the natural way
Переглядів 184 місяці тому
Netherlands-based Xeltis is “building” new blood vessels, using a novel nanofibre polymer, that get gradually transformed into living tissue. Watch Xeltis’ CEO Eliane Schutte talk about the advantages of their technology, and the Eindhoven company’s ambitions, in our latest edition of OptimumTV.
Using cell therapy to revolutionise treatment of end-stage liver disease
Переглядів 515 місяців тому
Using cell therapy to revolutionise treatment of end-stage liver disease
Optimum TV: How to get the most out of the 2024 spring conference season
Переглядів 216 місяців тому
Optimum TV: How to get the most out of the 2024 spring conference season
Optimum TV: Has spring finally sprung for biotech markets?
Переглядів 447 місяців тому
Optimum TV: Has spring finally sprung for biotech markets?
Relive the day: Optimum's 15th Annual Healthcare Investor Conference
Переглядів 48 місяців тому
Relive the day: Optimum's 15th Annual Healthcare Investor Conference
Reviews from the day: Optimum's 15th Annual Healthcare Investor Conference
Переглядів 98 місяців тому
Reviews from the day: Optimum's 15th Annual Healthcare Investor Conference
A Day in the Life as an Account Executive at Optimum Strategic Communications
Переглядів 100Рік тому
A Day in the Life as an Account Executive at Optimum Strategic Communications
Fireside Chat Francesco de Rubertis, Co-Founder & Partner of Medicxi and Mike Ward, Clarivate
Переглядів 93Рік тому
Fireside Chat Francesco de Rubertis, Co-Founder & Partner of Medicxi and Mike Ward, Clarivate
Optimum Q&A: Getting to know Dr. Cedric Francois, CEO of Apellis Pharmaceuticals
Переглядів 225Рік тому
Optimum Q&A: Getting to know Dr. Cedric Francois, CEO of Apellis Pharmaceuticals
Optimum Connections Q&A Renee Aguiar Lucander Trailer
Переглядів 30Рік тому
Optimum Connections Q&A Renee Aguiar Lucander Trailer
Global healthcare investing: Can hindsight hone the crystal ball for the future?
Переглядів 38Рік тому
Global healthcare investing: Can hindsight hone the crystal ball for the future?
Financing growth: Walking the tightrope - Annual Healthcare Investor Conference Insight
Переглядів 20Рік тому
Financing growth: Walking the tightrope - Annual Healthcare Investor Conference Insight
Can private markets continue to drive development in Life Sciences?
Переглядів 7Рік тому
Can private markets continue to drive development in Life Sciences?
Top takeaways from Mike Ward’s fireside chat with Werner Lanthaler, CEO of Evotec
Переглядів 23Рік тому
Top takeaways from Mike Ward’s fireside chat with Werner Lanthaler, CEO of Evotec
Optimum's Annual Healthcare Investor Conference | Industry Reviews
Переглядів 1712 роки тому
Optimum's Annual Healthcare Investor Conference | Industry Reviews